Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Pfizer PFE underwent analysis by 4 analysts in the last quarter ... the company may face hurdles in achieving optimal financial performance. Debt Management: Pfizer's debt-to-equity ratio is ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

Pharmaceutical stocks tumble as Trump announces imminent “major tariff” on imported drugs. Pfizer, Merck, and Johnson & Johnson shares drop over 4%, dragging the broader S&P 500 lower.

Access our full analysis of the earnings results here, it’s free. Originally spun off from Pfizer in 2013 as the ... guidance ...

Organizations that develop sophisticated approaches to IP risk management can protect their exit potential and create ...